CA2315877C - Facilitation de l'oxygenation associee a une hemodilution - Google Patents

Facilitation de l'oxygenation associee a une hemodilution Download PDF

Info

Publication number: CA2315877C
Authority: CA; Canada
Prior art keywords: blood; patient; oxygen; biocompatible; oxygen carrier
Prior art date: 1992-02-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 2315877

Other languages

English (en)

Other versions

CA2315877A1 (fr

Inventor

Duane J. Roth

Peter E. Keipert

Nicholas Simon Faithfull

Thomas F. Zuck

Jean G. Reiss

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alliance Pharmaceutical Corp

Original Assignee

Alliance Pharmaceutical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-02-26

Filing date

1993-02-26

Publication date

2003-05-13

1992-02-28 Priority claimed from US07/843,518 external-priority patent/US5344393A/en

1993-02-26 Application filed by Alliance Pharmaceutical Corp filed Critical Alliance Pharmaceutical Corp

1993-09-02 Publication of CA2315877A1 publication Critical patent/CA2315877A1/fr

2003-05-13 Application granted granted Critical

2003-05-13 Publication of CA2315877C publication Critical patent/CA2315877C/fr

2013-02-26 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 88
239000001301 oxygen Substances 0.000 title claims abstract description 88
229910052760 oxygen Inorganic materials 0.000 title claims abstract description 88
206010059484 Haemodilution Diseases 0.000 title description 42
210000004369 blood Anatomy 0.000 claims abstract description 140
239000008280 blood Substances 0.000 claims abstract description 140
238000000034 method Methods 0.000 claims abstract description 35
239000000203 mixture Substances 0.000 claims abstract description 26
239000007788 liquid Substances 0.000 claims abstract description 24
239000003814 drug Substances 0.000 claims abstract description 11
230000002708 enhancing effect Effects 0.000 claims abstract description 7
239000000839 emulsion Substances 0.000 claims description 64
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical group FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 30
238000001356 surgical procedure Methods 0.000 claims description 30
108010054147 Hemoglobins Proteins 0.000 claims description 17
102000001554 Hemoglobins Human genes 0.000 claims description 17
239000000084 colloidal system Substances 0.000 claims description 13
239000007789 gas Substances 0.000 claims description 11
230000029058 respiratory gaseous exchange Effects 0.000 claims description 11
241000282414 Homo sapiens Species 0.000 claims description 4
241001465754 Metazoa Species 0.000 claims description 4
230000037396 body weight Effects 0.000 claims description 4
208000014674 injury Diseases 0.000 claims description 4
230000008733 trauma Effects 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
239000000969 carrier Substances 0.000 abstract description 10
230000000004 hemodynamic effect Effects 0.000 abstract description 3
238000002360 preparation method Methods 0.000 abstract description 2
WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 30
210000004027 cell Anatomy 0.000 description 29
229960001217 perflubron Drugs 0.000 description 28
239000003633 blood substitute Substances 0.000 description 25
230000000747 cardiac effect Effects 0.000 description 24
210000001519 tissue Anatomy 0.000 description 24
238000009792 diffusion process Methods 0.000 description 21
238000005534 hematocrit Methods 0.000 description 19
230000001965 increasing effect Effects 0.000 description 17
241000282472 Canis lupus familiaris Species 0.000 description 15
230000036284 oxygen consumption Effects 0.000 description 13
230000001154 acute effect Effects 0.000 description 12
208000007502 anemia Diseases 0.000 description 10
150000003904 phospholipids Chemical class 0.000 description 9
239000003995 emulsifying agent Substances 0.000 description 8
239000003978 infusion fluid Substances 0.000 description 8
239000000243 solution Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
150000001875 compounds Chemical class 0.000 description 7
210000003743 erythrocyte Anatomy 0.000 description 7
TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 7
230000007423 decrease Effects 0.000 description 6
229940079593 drug Drugs 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000000463 material Substances 0.000 description 6
239000012071 phase Substances 0.000 description 6
230000008569 process Effects 0.000 description 6
239000008156 Ringer's lactate solution Substances 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000004888 barrier function Effects 0.000 description 5
238000010494 dissociation reaction Methods 0.000 description 5
230000005593 dissociations Effects 0.000 description 5
239000012530 fluid Substances 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
241000282412 Homo Species 0.000 description 4
-1 Pluronic F-68 Chemical class 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000004945 emulsification Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
238000001802 infusion Methods 0.000 description 4
BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
239000003058 plasma substitute Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
229920002307 Dextran Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000003190 augmentative effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000004087 circulation Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000000605 extraction Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000002357 osmotic agent Substances 0.000 description 3
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
230000002980 postoperative effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000009469 supplementation Effects 0.000 description 3
JTYRBFORUCBNHJ-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br JTYRBFORUCBNHJ-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 2
XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
ZJCFOZHHYJVNNP-UHFFFAOYSA-N F[C]Br Chemical compound F[C]Br ZJCFOZHHYJVNNP-UHFFFAOYSA-N 0.000 description 2
229920001612 Hydroxyethyl starch Polymers 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001010 compromised effect Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
210000000172 cytosol Anatomy 0.000 description 2
NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
239000008344 egg yolk phospholipid Substances 0.000 description 2
229940068998 egg yolk phospholipid Drugs 0.000 description 2
230000003028 elevating effect Effects 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
238000011049 filling Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004089 microcirculation Effects 0.000 description 2
LRMQIJUOLGKFKS-UHFFFAOYSA-N perfluoro-1,3-dimethyladamantane Chemical compound FC1(F)C(C2(F)F)(F)C(F)(F)C3(F)C(F)(F)C1(C(F)(F)F)C(F)(F)C2(C(F)(F)F)C3(F)F LRMQIJUOLGKFKS-UHFFFAOYSA-N 0.000 description 2
UIOCPFVEDHPJES-UHFFFAOYSA-N perfluoro-4-methylquinolizidine Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(C(F)(F)F)(F)N21 UIOCPFVEDHPJES-UHFFFAOYSA-N 0.000 description 2
JAJLKEVKNDUJBG-UHFFFAOYSA-N perfluorotripropylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F JAJLKEVKNDUJBG-UHFFFAOYSA-N 0.000 description 2
230000002688 persistence Effects 0.000 description 2
230000008288 physiological mechanism Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000000287 tissue oxygenation Effects 0.000 description 2
229960001295 tocopherol Drugs 0.000 description 2
239000011732 tocopherol Substances 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
KBHBUUBXEQUIMV-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluorooctane Chemical compound FC(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F KBHBUUBXEQUIMV-UHFFFAOYSA-N 0.000 description 1
VPQQZKWYZYVTMU-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,7-pentadecafluoroheptane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br VPQQZKWYZYVTMU-UHFFFAOYSA-N 0.000 description 1
SYVYTZLRTMPUCD-UHFFFAOYSA-N 1-chloro-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Cl SYVYTZLRTMPUCD-UHFFFAOYSA-N 0.000 description 1
XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035049 Blood-Borne Infections Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical class CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
102000010029 Homer Scaffolding Proteins Human genes 0.000 description 1
108010077223 Homer Scaffolding Proteins Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229940092232 albutein Drugs 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940082649 blood substitutes and perfusion irrigating solutions Drugs 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
229940119744 dextran 40 Drugs 0.000 description 1
229940119743 dextran 70 Drugs 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000011833 dog model Methods 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
238000002283 elective surgery Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
230000012953 feeding on blood of other organism Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000008570 general process Effects 0.000 description 1
108010036302 hemoglobin AS Proteins 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
229940064366 hespan Drugs 0.000 description 1
229940027278 hetastarch Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000002706 hydrostatic effect Effects 0.000 description 1
239000012216 imaging agent Substances 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000013010 irrigating solution Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
208000010555 moderate anemia Diseases 0.000 description 1
108010057694 modified fluid gelatins Proteins 0.000 description 1
229940074308 modified fluid gelatins Drugs 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000005445 natural material Substances 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
229950011087 perflunafene Drugs 0.000 description 1
MRQNKLRMROXHTI-UHFFFAOYSA-N perfluoro-N-methyldecahydroisoquinoline Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)N(C(F)(F)F)C(F)(F)C(F)(F)C21F MRQNKLRMROXHTI-UHFFFAOYSA-N 0.000 description 1
FRZFEPXEUZSBLA-UHFFFAOYSA-N perfluoroadamantane Chemical compound FC1(F)C(C2(F)F)(F)C(F)(F)C3(F)C(F)(F)C1(F)C(F)(F)C2(F)C3(F)F FRZFEPXEUZSBLA-UHFFFAOYSA-N 0.000 description 1
UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 1
RVZRBWKZFJCCIB-UHFFFAOYSA-N perfluorotributylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RVZRBWKZFJCCIB-UHFFFAOYSA-N 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
108010088880 plasmagel Proteins 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
201000000520 progressive familial heart block Diseases 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000000527 sonication Methods 0.000 description 1
241000894007 species Species 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
235000008979 vitamin B4 Nutrition 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Landscapes

Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 2315877 1992-02-26 1993-02-26 Facilitation de l'oxygenation associee a une hemodilution Expired - Fee Related CA2315877C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US07/843,518 US5344393A (en)	1992-02-28	1992-02-28	Use of synthetic oxygen carriers to facilitate oxygen delivery
US07/843,518		1992-02-28
CA002117528A CA2117528C (fr)	1992-02-28	1993-02-26	Facilitation de l'oxygenation associee a une hemodilution

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002117528A Division CA2117528C (fr)	1992-02-26	1993-02-26	Facilitation de l'oxygenation associee a une hemodilution

Publications (2)

Publication Number	Publication Date
CA2315877A1 CA2315877A1 (fr)	1993-09-02
CA2315877C true CA2315877C (fr)	2003-05-13

Family

ID=25677088

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2315877 Expired - Fee Related CA2315877C (fr)	1992-02-26	1993-02-26	Facilitation de l'oxygenation associee a une hemodilution

Country Status (1)

Country	Link
CA (1)	CA2315877C (fr)

1993
- 1993-02-26 CA CA 2315877 patent/CA2315877C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2315877A1 (fr)	1993-09-02

Legal Events

Date	Code	Title	Description
2000-08-18	EEER	Examination request
2005-02-28	MKLA	Lapsed

Publication	Publication Date	Title
CA2117528C (fr)	2000-11-21	Facilitation de l'oxygenation associee a une hemodilution
US5865784A (en)	1999-02-02	Method of hemodilution facilitated by monitoring oxygenation status
HK1010448B (en)	1999-06-17	Facilitated oxygen delivery in conjunction with hemodilution
AU629832B2 (en)	1992-10-15	Improved emulsions of highly fluorinated organic compounds
Riess	1992	Overview of progress in the fluorocarbon approach to in vivo oxygen delivery
US5869538A (en)	1999-02-09	Method for enhancing transport of gases to tissues
WO1991000110A1 (fr)	1991-01-10	Emulsions de fluorocarbones contenant des emulsifiants a base de phospholipides satures
Lane	1995	Perfluorochemical-based artificial oxygen carrying red cell substitutes
CA2315877C (fr)	2003-05-13	Facilitation de l'oxygenation associee a une hemodilution
Ohyanagi et al.	1986	Development and clinical application of perfluorochemical artificial blood
Mitsuno et al.	1988	Recent studies on perfluorochemical (PFC) emulsion as an oxygen carrier in Japan
Clark et al.	1997	Perfluorocarbons: future clinical possibilities
Keipert et al.	1994	Enhanced oxygen delivery by perflubron emulsion during acute hemodilution
Lowe	1994	Properties and biomedical applications of perfluorochemicals and their emulsions
MXPA97009697A (es)	1998-10-15	Hemodulacion facilitada por el monitoreo de la condicion de oxigenacion
Chang et al.	1987	Blood substitutes based on modified hemoglobin and fluorochemicals
AU4264100A (en)	2000-09-07	Hemodilution facilitated by mounting oxygenation status
Marchbank	1995	Fluorocarbon emulsions
Spiess	1998	Perfluorocarbon emulsions: Artificial gas transport media
Flaim	1997	Medical and therapeutic applications of perfluorocarbon-based products
Gollan et al.	1972	Experimental study of perfusion of rabbits with fluorocarbon fluid in the acute asanguineous state
Ottermann et al.	1985	Experiments with Haemoglobin Solutions